Among people with relapsing forms of multiple sclerosis (MS) and highly active disease, Mavenclad (cladribine) treatment resulted in stable or better cognitive function over two years. That’s according to new data from the Phase 4 CLARIFY-MS study (NCT03369665), which also demonstrated that Mavenclad can stabilize employment status for most people with full-time or part-time jobs. “The […]
The post Mavenclad helps MS patients keep cognitive skills sharp over 2 years appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com